Precipio Expands ICE COLD-PCR™ Menu for Breast, Colon and Endometrial Cancers
October 23, 2018 09:15 ET
|
Precipio, Inc.
Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO),...
Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability
October 23, 2018 09:13 ET
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based...
Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted in Media
October 18, 2018 07:36 ET
|
Precipio, Inc.
Articles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology NEW HAVEN, Conn., Oct. 18, 2018 (GLOBE NEWSWIRE) -- The scientific and economic advantages of the...
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
October 17, 2018 08:30 ET
|
Todos Medical Ltd.
REHOVOT, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Todos Medical, Ltd. Inc. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early...
Two new Board of Director appointments to liquid biopsy company Clinical Genomics
October 16, 2018 08:30 ET
|
Clinical Genomics
BRIDGEWATER, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading provider of cancer testing solutions and liquid biopsy testing, today announced two appointments to the company’s...
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
October 16, 2018 07:47 ET
|
Precipio, Inc.
Fourth consecutive Quarter of Triple-Digit Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased 163% over First Three Quarters of 2017 NEW HAVEN, Conn., Oct. 16, 2018 (GLOBE...
Precipio Granted 180 Day NASDAQ Extension to Regain Compliance
September 27, 2018 07:37 ET
|
Precipio, Inc.
Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, Conn., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Specialty cancer...
VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
September 24, 2018 06:00 ET
|
VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...
Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M
September 21, 2018 09:18 ET
|
Precipio, Inc.
$82,000 monthly debt service to be eliminated with notes convertible into equity at a 65% premium to market NEW HAVEN, Conn., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics Company...
Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering
September 20, 2018 07:37 ET
|
Precipio, Inc.
New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced...